- Home
- AMBO vs LIXT Comparison
AMBO vs LIXT Comparison
Compare AMBO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- LIXT
- Stock Information
- Founded
- AMBO 2000
- LIXT 2005
- Country
- AMBO United States
- LIXT United States
- Employees
- AMBO N/A
- LIXT N/A
- Industry
- AMBO Other Consumer Services
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- LIXT Health Care
- Exchange
- AMBO Nasdaq
- LIXT Nasdaq
- Market Cap
- AMBO 5.1M
- LIXT 4.1M
- IPO Year
- AMBO 2010
- LIXT N/A
- Fundamental
- Price
- AMBO $1.42
- LIXT $2.02
- Analyst Decision
- AMBO
- LIXT
- Analyst Count
- AMBO 0
- LIXT 0
- Target Price
- AMBO N/A
- LIXT N/A
- AVG Volume (30 Days)
- AMBO 157.1K
- LIXT 32.5K
- Earning Date
- AMBO 12-27-2024
- LIXT 11-12-2024
- Dividend Yield
- AMBO N/A
- LIXT N/A
- EPS Growth
- AMBO N/A
- LIXT N/A
- EPS
- AMBO N/A
- LIXT N/A
- Revenue
- AMBO $9,163,000.00
- LIXT N/A
- Revenue This Year
- AMBO N/A
- LIXT N/A
- Revenue Next Year
- AMBO N/A
- LIXT N/A
- P/E Ratio
- AMBO N/A
- LIXT N/A
- Revenue Growth
- AMBO N/A
- LIXT N/A
- 52 Week Low
- AMBO $1.00
- LIXT $1.31
- 52 Week High
- AMBO $6.30
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- AMBO 40.93
- LIXT 51.26
- Support Level
- AMBO $1.35
- LIXT $1.85
- Resistance Level
- AMBO $1.56
- LIXT $2.65
- Average True Range (ATR)
- AMBO 0.18
- LIXT 0.21
- MACD
- AMBO -0.05
- LIXT -0.01
- Stochastic Oscillator
- AMBO 7.55
- LIXT 21.18
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.